Skip to main content
. Author manuscript; available in PMC: 2012 Apr 15.
Published in final edited form as: Blood Cells Mol Dis. 2011 Apr 15;46(4):318–320. doi: 10.1016/j.bcmd.2011.02.006

Figure 1. Effect of Rapamycin treatment ex-vivo on human CB CD34+ engraftment of sublethaly-irradiated NSG mice.

Figure 1

NSG mice were transplanted with either (A) 100,000 or 50,000 or (B) 60,000 or 30,000 rapamycin or control treated CD34+ CB cells 24 hours after sublethal irradiation. After 5 months, bone marrow from primary recipients of CB were transplanted into secondary recipients. Peripheral blood was collected at different time points after transplantation and assessed for percentage of human CD45+ cells present. Results are shown for 3–5 primary recipients each and 5 recipients for secondary transplants using pooled BM cells from the primary recipients. Data, for each of the two different experiments with different CB collections, were analyzed statistically using the Student’s t test. A P value less than 0.05 was considered statistically significant. Significance compared to control treated cells for that number of transplanted cells.